Welcome to our dedicated page for Tela Bio SEC filings (Ticker: TELA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TELA Bio, Inc. (NASDAQ: TELA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. TELA Bio is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, and its filings offer detailed information on financial performance, capital structure, governance, and material agreements that affect TELA stock.
Investors can review current reports on Form 8-K, where TELA Bio reports material events such as entry into significant credit agreements, registered direct offerings of common stock and pre-funded warrants, and changes in directors and compensatory arrangements. For example, the company has filed 8-Ks describing a senior secured term loan facility with Perceptive Credit Holdings V, LP, the terms of associated warrants to purchase common stock, and the termination of a prior credit and security agreement. Other 8-Ks furnish press releases announcing quarterly financial results and updated investor presentations.
Through its periodic reports (10-K and 10-Q, accessible via EDGAR and summarized on this page), users can analyze TELA Bio’s revenue, gross profit, operating expenses, and net loss, as well as balance sheet items such as cash, long-term debt, and stockholders’ equity. These filings also contain risk factor discussions covering macroeconomic conditions, surgical procedure volumes, competition, product development and manufacturing issues, and reimbursement considerations.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand major changes in revenue trends, liquidity, debt covenants, and equity offerings. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks, and related exhibits appear promptly, while insider and equity-related disclosures such as warrant issuances and director equity awards can be examined alongside the underlying text.
For anyone researching TELA Bio’s regulatory history, financing arrangements, and board-level changes, this filings page offers a structured view of the company’s official disclosures with AI assistance to interpret complex legal and financial language.
TELA Bio director Betty Jo Rocchio filed an initial Form 3 reporting no securities beneficially owned as of 10/09/2025. The filing lists her relationship to the issuer as a director and was signed by an attorney-in-fact on 10/10/2025. No non-derivative or derivative holdings are reported and Exhibit 24 (Power of Attorney) is attached.
TELA Bio reported a change in its board of directors. On October 4, 2025, director Lisa Colleran resigned from the Board and from the Nominating and Corporate Governance and Audit Committees, and her resignation was not due to any disagreement with the company’s operations, policies, or practices.
On October 7, 2025, the Board appointed Dr. Betty Jo Rocchio as a Class I director, effective October 9, 2025, with a term running until the 2026 annual meeting. She is an experienced senior nursing executive and has been deemed an independent director under Nasdaq rules, with no related-party or family relationships disclosed.
In connection with her appointment, Dr. Rocchio received an initial equity package of an option for 17,550 shares and 11,925 restricted stock units, vesting over three years, plus an annual cash retainer of $45,000. Beginning with the 2026 annual meeting, she is eligible for recurring annual equity awards of options for 11,700 shares and 7,950 restricted stock units, subject to continued service.
Laurence W. Lytton reports beneficial ownership of 3,424,191 shares of TELA Bio common stock, representing 8.5% of the outstanding class based on 39,616,440 shares. The position consists of 2,724,191 shares of common stock and 700,000 shares issuable upon exercise of outstanding warrants. The filing states the reporting person has sole voting power and sole dispositive power over all reported shares.
The filer certified the securities were not acquired to change or influence control of the issuer, indicating this disclosure reflects a substantial passive stake. The inclusion of warrants means the economic exposure and potential future share count may change if those instruments are exercised.
TELA Bio filed a Form S-8 to register 3,500,000 additional shares of common stock under its Amended and Restated 2019 Equity Incentive Plan. The board adopted an amendment and the company’s stockholders approved it, and this filing registers the Additional Shares for issuance under the Amended Equity Plan. After this increase, a total of 7,432,620 shares are registered for issuance under the plan. The filing incorporates prior S-8 registration statements by reference and attaches the Amended Equity Plan and related exhibits.
TELA Bio reported continued commercial growth with revenue of $20.2 million for the quarter ended June 30, 2025, a 26% increase from $16.1 million a year earlier, and $38.7 million for the six months, up 18% year-over-year. Gross profit for the quarter was $14.1 million. Quarterly net loss narrowed to $9.9 million (EPS -$0.22) from $12.6 million, while the six-month net loss was $21.2 million versus $18.3 million, noting the prior-year six-months included a $7.6 million gain on the sale of the NIVIS product line.
Balance sheet and liquidity show $34.98 million in cash and cash equivalents (restricted cash brings cash per statements of cash flows to $35.24 million), total assets of $67.54 million and total liabilities of $58.35 million. The company carries total debt of $41.38 million (long-term portion $38.05 million) under a MidCap term loan maturing in 2027 with covenants including minimum net revenue tests. Product mix for the quarter was $12.49 million OviTex and $7.33 million OviTex PRS, with international sales of $3.0 million. The company discloses an accumulated deficit of $379.9 million and says it expects to incur losses for the foreseeable future.
TELA Bio, Inc. furnished a press release reporting its financial results for the quarter ended June 30, 2025 and provided an updated corporate slide deck for investor meetings. The Form 8-K identifies the relevant disclosure items as Item 2.02 (results of operations and financial condition) and Item 7.01 (Regulation FD disclosure), and lists exhibits including the press release (Exhibit 99.1), the slide deck (Exhibit 99.2) and the Inline XBRL cover page (Exhibit 104). The filing notes these materials are furnished, not filed, and the document is signed by CEO Antony Koblish. The company’s common stock trades on Nasdaq under the symbol TELA and the registrant indicates emerging growth company status.